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Abstract
Intubation of the airway can lead to laryngotracheal injury, resulting
in extubation failure from upper airway obstruction (UAO). A
number of factors can help to identify patients who are at greatest
risk for postextubation UAO. Three randomized controlled trials
demonstrate that prophylactic corticosteroids decrease the risk for
postextubation UAO and probably the need for re-intubation.
Extubation failure (the need for re-intubation) is associated
with increased intensive care unit and hospital mortality,
increased length of stay in the intensive care unit and
hospital, greater need for tracheostomy and for long-term
acute care, and increased costs. Underlying severity of
illness, premorbid health status, and complications directly
associated with re-intubation fail to explain the adverse
outcomes seen with extubation failure. Clinical deterioration
between the time of extubation and the re-establishment of
ventilatory support may provide the best explanation.
Therefore, preventing extubation failure has the potential to
improve outcome.
The study reported by Lee and coworkers [1] is one of a
series of recent investigations examining whether cortico-
steroids can prevent postextubation upper airway obstruction
(UAO), which is a common cause of extubation failure.
Intubation and the endotracheal tube (ETT) may cause
laryngotracheal injury, resulting in inflammation, mucosal
ulceration, edema, or granuloma formation. This can lead to
glottic or subglottic narrowing, which manifests as stridor,
respiratory distress, or respiratory failure after removal of the
ETT. Factors associated with increased risk for post-
extubation UAO include female sex (probably resulting from
small airway size), trauma patient, age above 80 years,
excessively mobile or overly large ETT size, ratio of ETT size
to laryngeal diameter above 45%, ratio of patient height to
tube diameter, duration of intubation, tracheal infection,
absence of cough, absence of sedation, low Glasgow Coma
Scale score, or excess cuff pressure [2-5].
Research into detection of UAO, with the ETT in place, has
recently focused on using the quantitative cuff leak test [6].
During this maneuver the patient breathes on assist control
ventilation, the endotracheal cuff is deflated, and the
difference between inspired and expired tidal volume is
compared. An obstructed upper airway results in similar
inspiratory and expiratory volumes, whereas a patent airway
results in a substantial difference as a large volume of gas
escapes around the tube. This quantitative cuff leak can be
reported as either a percentage of inspired tidal volume or as
an absolute cuff leak volume (CLV). Previous investigators
have found that the risk for postextubation stridor is increased
when CLV is less than approximately 12% to 25% of inspired
volume or an absolute value of less than 110 to 130 ml
[2,6-9].
Although previous studies conducted in pediatric patients
found that corticosteroids reduce the prevalence of post-
extubation UAO by nearly 40% and may reduce the need for
re-intubation [10], earlier controlled trials in mechanically
ventilated adults did not corroborate those findings [11].
Francois and colleagues [12] recently compared 20 mg
methylprednisolone (given every 4 hours for 12 hours before
extubation) with placebo in nearly 700 adults patients who
had been intubated for at least 36 hours. Corticosteroid
pretreatment was associated with decreased risk for post-
extubation UAO (3% versus 22%), need for re-intubation (4%
versus 8%), and need for re-intubation secondary to UAO
(0.3% versus 4%). The number needed to treat (NNT) was
eight to prevent one case of stridor and 26 to prevent one
case of re-intubation. Cheng and colleagues [2] used a
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reduced CLV (≤24% of inspired tidal volume) to define and
study patients at high risk for postextubation UAO. Patients
randomly assigned to methylprednisolone (40 mg every
6 hours for four doses) were less likely either to experience
stridor (7% versus 30%) or to require re-intubation (7%
versus 19%) than were those receiving placebo.
The study reported in this issue of Critical Care [1] also
targeted high-risk patients by examining those ventilated for
at least 48 hours and with a CLV below 110 ml. Patients
were randomly assigned to receive placebo or dexametha-
sone 5 mg every 6 hours for 24 hours, and were then
extubated 24 hours later. The dexamethasone group was less
likely to develop postextubation stridor (10% versus 27.5%;
NNT = 5.7) without a difference in need for re-intubation
(2.5% versus 5%; NNT =40). An important observation is
that dexamethasone led to a significant increase in CLV that
persisted for 24 hours after the last dose (for example, at the
time of extubation). Given that no further improvement in CLV
occurred after the last dose of dexamethasone, one could
argue for immediate extubation at that time rather than
waiting an additional 24 hours.
The study by Lee and coworkers [1] also revealed that 14 out
of 285 in the non-randomized cohort (4.9%), who had a CLV
above 110 ml, developed stridor. Examining these patients
and those randomly assigned to placebo, only 20% with
postextubation UAO required re-intubation, possibly a result
of the effective use of inhaled racemic adrenaline (epi-
nephrine) and noninvasive ventilation. Among placebo
patients, 73% did not develop postextubation UAO, despite a
CLV below 110 ml; similar findings have been noted by other
investigators. A falsely low CLV may result from secretions
adherent to or pooled around the ETT. Alternatively, with the
cuff deflated, the patient may breathe additional tidal volume
around the tube (in addition to machine delivered volume),
leading to a falsely low measurement of inspired tidal volume.
The resulting difference between inspired and expired tidal
volume will then be falsely low. This phenomenon can be
overcome by delivering the machine breath with the cuff
inflated and then deflating the cuff just before expiration [13].
The evidence is now mounting that corticosteroids can
prevent postextubation UAO, and possibly the need for re-
intubation, but should all patients be intubated for longer than
36 to 48 hours receive such therapy? Although a short
course of corticosteroids may be relatively safe, further study
is warranted. This author believes the focus should continue
to be on targeting patients at greatest risk. Although the
study by Francois and coworkers [12] examined an
‘unselected’ cohort, the 22% incidence of postextubation
UAO suggests a high risk group. Using the CLV can help to
identify a cohort at greater risk, but the sensitivity and
specificity of the test is suboptimal. Using this test alone to
determine need for prophylactic corticosteroids will result in
an unnecessary 12 to 24 hour prolongation of intubation for
three out of every four such patients. Another approach is to
identify first a high-risk cohort based on clinical factors (for
instance, age, sex, tube size, and so on) and then to apply
CLV to determine which patients should receive cortico-
steroids before extubation.
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